Synageva BioPharma Receives European Orphan Medicinal Product Designation for SBC-102 for Lysosomal Acid Lipase Deficiency

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company’s enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.
MORE ON THIS TOPIC